Division of Cancer Prevention

Prostate Cancer Prevention and Finasteride: A Conversation with NCI’s Dr. Howard Parnes

In 2003, results from the Prostate Cancer Prevention Trial (PCPT)—an NCI-funded randomized clinical trial with nearly 19,000 participants—showed that men aged 55 and older who used the drug finasteride daily for 7 years had a substantially reduced risk of developing prostate cancer.

In this interview, Howard Parnes, MD, of NCI’s Division of Cancer Prevention and a PCPT investigator, talks about the findings from these subsequent studies and what they mean for the use of finasteride today.

Read the NCI Cancer Currents Blog post

NCORP Tissue Procurement Protocol to Open at 12 Community Sites

At 12 NCI Community Oncology Research Program (NCORP) sites across the United States, a new kind of study will soon be opening for patients with advanced malignancies being treated with molecularly targeted therapies. The NCORP Tissue Procurement Protocol (NCI 10231, NCT 03707574) is not a treatment trial, but a study to assess if researchers can obtain tissue and blood samples at baseline and upon progression in patients with advanced cancer being treated with molecularly targeted therapies.

Read the NCI DCP News Note

Cancer Prevention Fellowship Program (CPFP) Application Period Open

The NCI Cancer Prevention Fellowship Program (CPFP), which supports postdoctoral research and leadership training, is accecpting applications for the fellows' class to commence in 2020.  The application period is open until August 19, 2019, for researchers, scientists, or clinicians with a demonstrated interest in cancer prevention.

Learn more about the NCI Cancer Prevention Fellowship Program